Moxazocine

moxazocine_structure.svg

Moxazocine is a synthetic opioid analgesic that was developed in the 1970s. It is a member of the benzomorphan class of opioids and is known for its potent analgesic properties. Moxazocine has been studied for its potential use in pain management, but it has not been widely adopted in clinical practice.

Pharmacology

Moxazocine acts primarily as an agonist at the kappa-opioid receptor (KOR) and has partial agonist activity at the mu-opioid receptor (MOR). The activation of KOR is associated with analgesia, dysphoria, and psychotomimetic effects, while MOR activation typically results in euphoria, analgesia, and respiratory depression. The unique receptor profile of moxazocine contributes to its distinct pharmacological effects compared to other opioids.

Clinical Use

Despite its potent analgesic properties, moxazocine has not been widely used in clinical settings. This is partly due to its side effect profile, which includes significant dysphoria and psychotomimetic effects that limit its acceptability among patients. Additionally, the development of other opioid analgesics with more favorable side effect profiles has overshadowed the potential use of moxazocine.

Side Effects

The side effects of moxazocine are similar to those of other opioids and include:

• Nausea
• Vomiting
• Constipation
• Dysphoria
• Psychotomimetic effects
• Respiratory depression

Legal Status

Moxazocine is not widely available and is not listed as a controlled substance in many countries. However, its use is limited to research settings, and it has not been approved for medical use by major regulatory agencies such as the Food and Drug Administration (FDA) or the European Medicines Agency (EMA).

Research

Research on moxazocine has primarily focused on its pharmacological properties and potential therapeutic applications. Studies have explored its efficacy in pain management and its side effect profile compared to other opioids. However, due to its limited clinical use, research on moxazocine has been relatively sparse.

See Also

• Opioid
• Analgesic
• Kappa-opioid receptor
• Mu-opioid receptor
• Benzomorphan

External Links

‎